YU48636B - Dimerni derivati žučnih kiselina i postupak za njihovo dobijanje - Google Patents

Dimerni derivati žučnih kiselina i postupak za njihovo dobijanje

Info

Publication number
YU48636B
YU48636B YU189991A YU189991A YU48636B YU 48636 B YU48636 B YU 48636B YU 189991 A YU189991 A YU 189991A YU 189991 A YU189991 A YU 189991A YU 48636 B YU48636 B YU 48636B
Authority
YU
Yugoslavia
Prior art keywords
bile acid
procedure
preparation
gallic acids
dimeric derivatives
Prior art date
Application number
YU189991A
Other languages
English (en)
Other versions
YU189991A (sh
Inventor
Werner dr. Kramer
Gunther Dr. Wess
Stefan dr. Mullner
Horst dr. Neubauer
Original Assignee
Heochst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heochst Aktiengesellschaft filed Critical Heochst Aktiengesellschaft
Priority to SI9111899A priority Critical patent/SI9111899B/sl
Priority to HR940751A priority patent/HRP940751B1/xx
Publication of YU189991A publication Critical patent/YU189991A/sh
Publication of YU48636B publication Critical patent/YU48636B/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Abstract

Dimerni derivati zucnih kiselina sa formulom I, na znaceni time, sto G1-X-G1 (I) je G1 jedinjenje sa formulom II u kojoj Y predstavlja slobodnu valencu za vezivanje grupe X ili ima sledeca znacenja -OL, -NHL, -NL2, amino kiselina ili aminosulfonska kiselina vezane preko amino grupe, kao npr. -NHCH2-CO2H,-NH-CH2CH2-SO3H, i njihovi (C1-C4)-alkil estri i soli alkalnih i zemnoalkalnih metala, -OKa, gde je Ka katjon, kao na primer jon alkalnog ili zemnoalkalnog metala ili alternativno kvartarni amonijum jon i gde L predstavlja H, zasicen ili nezasicen alkil ostatak sa 1-10 ugnjenikovih atoma, razgranat ili nerazgranat, cikloalkil ostatak sa 3-8 ugljenikovih atoma, fenil ostatak nesupstituisan ili jednom do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil, ili (C1-C4)-alkoksi, benzil ostatak, nesupstituisan ili jednom do tri puta supstituisan F, Cl, Br, (C1-C4)-alkilom ili (C1-C4)-alkoksi, i R6je metil, izopropil, izobutil, 2-butil, benzil, 4-hidroksibenzil, hidroksimetil, 1-hidroksietil, H3CSH2CH2-, HO2CCH2- ili HO2CCH2CH2-, R1 je slobodna valenca za vezivanje grupa X ili H, zasicen ili nezasicen alkil ostatak sa 1-10 atoma ugljenika, razgranatih ili nerazgranatih, cikloalkil ostatak sa 3-8 ugljenikovih atoma, fenil ostatak koji je nesupstituisan ili jedanput do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)- alkoksi, -N+H3, -OPO3-,benzil ostatak nesupstituisan u prstenu ili jedanput do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)-alkoksi, -N+H3, -OPO3-,ili fenil koji moze biti jedanput ili tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)-alkoksi, -N+H3, -OPO3-,bifenilmetil ostatak koji je nesupstituisan ili jedanput do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)-alkoksi, -N+H3, -OPO3-,trifenilmetil ostatak koji je nesupstituisan ili jedanput do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)-alkoksi, -N+H3, -OPO3-,1- ili 2-naftilmetil ostatak koji je nesupstituisan ili jedanput do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)-alkoksi, -N+H3, -OPO3-,9-fluorenil ostatak koji je nesupstituisan ili jedanput do tri puta supstituisan F, Cl, Br, (C1-C4)-alkil ili (C1-C4)-alkoksi, -N+H3, -OPO3-, 2-, 3-, ili 4-piridil ostatak, ostatak gde L ima gore dato znacenje, R2 do R5 gde R2 i R3 ili R4 i R5 u svakom slucaju zajedno su kiseonik karbonilne grupe ili pojedinacno i u svakom slucaju nezavisno jedan od drugog su gde L ima gore dato znacenje i T oznacava L ili slobodnu valencu za vezivanje grupe X,sa ogranicenjem da samo jedna slobodna velenca za vezivanje grupe X pocinje od G1, X je jednostruka veza ili grupa sa formulom III gde je A alkilenski lanac, razgranat ili nerazgranat, zasicen ili nezasicen i opcionalno moze biti prekinut u lancu -O-, -S- ili arilenom, a narocito fenilenom, gde su veze na sledecim mestima: i lanac obuhvata ukupno 2 do 12, prvenstveno 2 do 6 clanova lanca p, B je alkilenski lanac, razgranat ili nerazgranat, zasicen ili nezasicen i opcionalno moze biti prekinut u
YU189991A 1990-12-06 1991-12-06 Dimerni derivati žučnih kiselina i postupak za njihovo dobijanje YU48636B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI9111899A SI9111899B (sl) 1990-12-06 1991-12-06 Derivati žolčnih kislin, postopke za njihovo pripravo in uporaba teh spojin kot zdravila
HR940751A HRP940751B1 (en) 1990-12-06 1994-10-25 Bile-acid derivatives, a process for their preparation and their use as medicines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4038833 1990-12-06

Publications (2)

Publication Number Publication Date
YU189991A YU189991A (sh) 1995-10-03
YU48636B true YU48636B (sh) 1999-03-04

Family

ID=6419672

Family Applications (1)

Application Number Title Priority Date Filing Date
YU189991A YU48636B (sh) 1990-12-06 1991-12-06 Dimerni derivati žučnih kiselina i postupak za njihovo dobijanje

Country Status (23)

Country Link
US (1) US5250524A (sh)
EP (1) EP0489423B1 (sh)
JP (1) JP3237882B2 (sh)
KR (1) KR100221690B1 (sh)
AT (1) ATE144988T1 (sh)
AU (1) AU649089B2 (sh)
CA (1) CA2057099C (sh)
CZ (1) CZ281075B6 (sh)
DE (1) DE59108326D1 (sh)
DK (1) DK0489423T3 (sh)
ES (1) ES2096614T3 (sh)
FI (1) FI106800B (sh)
GR (1) GR3021572T3 (sh)
HR (1) HRP940751B1 (sh)
HU (2) HU213402B (sh)
IE (1) IE914235A1 (sh)
IL (1) IL100240A (sh)
NO (1) NO304187B1 (sh)
NZ (1) NZ240846A (sh)
PT (1) PT99713B (sh)
SI (1) SI9111899B (sh)
YU (1) YU48636B (sh)
ZA (1) ZA919605B (sh)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
ES2087422T3 (es) * 1991-12-20 1996-07-16 Hoechst Ag Polimeros y oligomeros de derivados de acidos biliares, procedimiento para su preparacion y su empleo como medicamento.
EP0548793A3 (en) * 1991-12-20 1995-11-02 Hoechst Ag Ethylenic-unsaturated bile acid derivatives, process for their production and preliminary processes therefor
IT1258788B (it) * 1992-01-17 1996-02-29 Giuliani Spa Derivati solforati di acidi biliari
DE59307759D1 (de) * 1992-06-12 1998-01-15 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel
ES2104208T3 (es) * 1993-03-09 1997-10-01 Hoechst Ag Procedimiento para la preparacion de derivados de acido 3beta-aminocolanico.
JP3546886B2 (ja) * 1993-03-10 2004-07-28 ジェネーラ コーポレーション ステロイド誘導体、それらを含む薬剤組成物、及び抗生物質又は消毒薬としてのそれらの使用
TW289757B (sh) * 1993-05-08 1996-11-01 Hoechst Ag
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289021B (sh) * 1993-05-08 1996-10-21 Hoechst Ag
TW289020B (sh) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5585470A (en) * 1994-06-23 1996-12-17 Transcell Technologies, Inc. Process for the manufacture of 3-amino-substituted glycosylated bile acids
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
FR2743561B1 (fr) * 1996-01-15 1998-02-20 Fournier Sca Lab Derives de steroides, procede de preparation et utilisation en therapeutique
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
JP2000510460A (ja) * 1996-04-26 2000-08-15 マゲイニン・ファーマシューティカルズ・インコーポレーテッド スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
DE19633268A1 (de) * 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DK0869121T3 (da) * 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845403B4 (de) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19950686B4 (de) * 1999-10-21 2006-06-29 Martin-Luther-Universität Halle-Wittenberg Multifunktionelle Spacer
JP2004506599A (ja) * 1999-12-09 2004-03-04 ジェネーラ・コーポレーション 喘息および関連疾患を含むアトピー性アレルギーを処置するための標的としての喘息関連因子
AU5342701A (en) * 2000-04-12 2001-10-30 Genaera Corp A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
US8975246B2 (en) 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
US20030170216A1 (en) * 2001-12-20 2003-09-11 Schering-Plough Corporation SYN3 compositions and methods
US7141559B2 (en) 2002-06-19 2006-11-28 Karo Bio Ab Glucocorticoid receptor ligands for the treatment of metabolic disorders
PT1551860E (pt) * 2002-06-19 2007-02-28 Karobio Ab Ligandos de receptores glucocorticóides para o tratamento de distúrbios metabólicos
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CN1845932A (zh) 2003-06-04 2006-10-11 坎基股份有限公司 转染剂
US7235678B2 (en) * 2004-03-30 2007-06-26 Council Of Scientific And Industrial Research Bile acid derived steroidal dimers with novel amphiphilic topology having antifungal activity
US20050225942A1 (en) * 2004-04-07 2005-10-13 First International Computer Inc. Plug-in cooling device
ES2318922B1 (es) * 2005-05-30 2010-02-12 Universidade De Santiago De Compostela Nuevos dimeros derivados de acidos biliares funcionalizados en la posicion 3 del anillo a. metodo para la sintesis y aplicaciones.
ES2318927B1 (es) * 2005-08-25 2010-02-12 Universidade De Santiago De Compostela Nuevos dimeros de acidos biliares funcionalizados en la posicion 24 de la cadena alquilica de la sal biliar. procedimientos para su obtencion y aplicaciones.
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
US7962543B2 (en) * 2007-06-01 2011-06-14 Advanced Micro Devices, Inc. Division with rectangular multiplier supporting multiple precisions and operand types
KR101289199B1 (ko) 2008-08-28 2013-07-29 한양대학교 산학협력단 수용성기를 포함한 바일산 유도체 및 그의 응용
WO2012054092A1 (en) * 2010-01-22 2012-04-26 Trustees Of Dartmouth College Lipid cofactors for facilitating propogation of prpsc
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SI2637668T1 (sl) 2010-11-08 2016-11-30 Albiero Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CA2815698C (en) 2010-11-08 2019-04-30 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EA029581B1 (ru) 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
CA3087898A1 (en) 2018-02-02 2019-08-08 Ripple Therapeutics Corporation Glass formulations comprising steroid dimers and uses thereof
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
AU2020218908A1 (en) 2019-02-06 2021-08-26 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
MX2021009622A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023216423A1 (zh) * 2022-05-13 2023-11-16 苏州慧疗生物医药科技有限公司 脂质化合物及其组合物,制备和用途
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418059A (en) * 1981-07-20 1983-11-29 Montefiore Medical Center Nucleoside ester compositions
IT1210874B (it) * 1982-04-15 1989-09-29 Istituto Chemioterapico Sale di magnesio dell'acido chenodesossicolico e dell'acido ursodesossicolico, processo per lasua preparazione e composizioni terapeutiche che lo contengono come principio attivo.
EP0202703B1 (en) * 1985-05-15 1989-08-09 N.V. Gantax Pharmaceutica Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein
DE3742798C2 (de) * 1987-12-17 1997-02-13 Freedom Chemical Co Verfahren zur Herstellung des Magnesium-Doppelsalzes der Chenodesoxycholsäure und Ursodesoxycholsäure

Also Published As

Publication number Publication date
KR920012108A (ko) 1992-07-25
FI915719A0 (fi) 1991-12-04
HU913817D0 (en) 1992-02-28
CS369791A3 (en) 1992-06-17
IL100240A (en) 1995-10-31
SI9111899B (sl) 2000-06-30
CA2057099A1 (en) 1992-06-07
ATE144988T1 (de) 1996-11-15
NO914792L (no) 1992-06-09
FI106800B (fi) 2001-04-12
US5250524A (en) 1993-10-05
SI9111899A (sl) 1998-04-30
AU649089B2 (en) 1994-05-12
CZ281075B6 (cs) 1996-06-12
HU211900A9 (en) 1996-01-29
EP0489423A1 (de) 1992-06-10
HRP940751B1 (en) 2000-12-31
FI915719A (fi) 1992-06-07
NO914792D0 (no) 1991-12-05
IE914235A1 (en) 1992-06-17
HRP940751A2 (en) 1997-04-30
AU8884991A (en) 1992-06-11
PT99713A (pt) 1992-10-30
HUT62599A (en) 1993-05-28
PT99713B (pt) 1999-05-31
GR3021572T3 (en) 1997-02-28
JP3237882B2 (ja) 2001-12-10
HU213402B (en) 1997-06-30
ZA919605B (en) 1992-08-26
NZ240846A (en) 1994-04-27
EP0489423B1 (de) 1996-11-06
CA2057099C (en) 2005-05-17
KR100221690B1 (ko) 1999-10-01
YU189991A (sh) 1995-10-03
DE59108326D1 (de) 1996-12-12
ES2096614T3 (es) 1997-03-16
DK0489423T3 (da) 1997-04-14
JPH05294988A (ja) 1993-11-09
IL100240A0 (en) 1992-09-06
NO304187B1 (no) 1998-11-09

Similar Documents

Publication Publication Date Title
YU48636B (sh) Dimerni derivati žučnih kiselina i postupak za njihovo dobijanje
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
DK162883D0 (da) N-glucosylerede carboxylsyreamidderivater, fremgangsmade til fremstilling heraf samt deres anvendelse til pavirkning af organismens egen forsvarsmekanisme
ATE131471T1 (de) An fette gebundene aminosäuren, peptide oder deren derivate
DE59711908D1 (de) Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
ATE31300T1 (de) Imidazol-2-yl-mercaptoalkansaeuren, verfahren zu deren herstellung und pharmazeutische formulierungen welche diese enthalten.
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
IL91212A0 (en) 6-fluoro-3,5-dihydroxy carboxylic acids and derivatives thereof,a process for the preparation thereof and pharmaceutical compositions containing them
IL86638A0 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives,their preparation and their use as pesticides
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
ES2087421T3 (es) Acidos (1's)-hidroxialquiloxapenem-3-carboxilicos y su uso como inhibidor de la betalactamasa.
NO913685D0 (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
DE69509822T2 (de) Verfahren zur Herstellung von Ascorbinsäurederivaten
DK0741746T3 (da) Thymosin alpha 1-analoger
DE69201873T2 (de) Verfahren zur Herstellung optisch aktiver Dihydropyranderivate.